- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Triple Combination Therapy Effective for Drug-Naive Type 2 Diabetes Patients, shows new Study
Korea: A study has demonstrated that initiating treatment with a triple combination therapy (TCT) comprising metformin, dapagliflozin, and saxagliptin is both safe and effective for drug-naive patients diagnosed with type 2 diabetes (T2D) when compared to stepwise add-on therapy (SAT).
"Compared to SAT, initial TCT effectively lowered HbA1c levels with higher tolerability and safety for 104 weeks among newly diagnosed patients with T2D," the researchers reported. The findings from the TRIPLE-AXEL study, published in Diabetes, Obesity and Metabolism, suggest a novel strategy for initial combination therapy in type 2 diabetes patients.
Nam Hoon Kim, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea, and colleagues aimed to evaluate the tolerability and efficacy of an initial triple combination therapy compared with conventional stepwise add-on therapy in patients with newly diagnosed type 2 diabetes.
For this purpose, the research team conducted a multicentre, randomized, 104-week, open-label trial comprising 105 patients with drug-naïve T2D (with HbA1c level ≥ 8.0%, < 11.0%). They were randomized to the TCT (1000 mg of metformin, 10 mg of dapagliflozin, and 5 mg of saxagliptin once daily) or SAT (initiated with metformin, followed by glimepiride and sitagliptin) groups.
The primary measure of success was the percentage of patients achieving an HbA1c level below 6.5% without experiencing hypoglycemia, gaining 5% or more in weight, or needing to stop medications due to adverse events by the 104-week mark.
The study led to the following findings:
- HbA1c reduction from baseline at week 104 was similar between the groups (the least squares mean change was −2.56% in the TCT group vs. –2.75% in the SAT group).
- The primary outcome was achieved in 39.0% and 17.1% of the TCT and SAT groups, respectively, with a risk difference of 22.0.
- HbA1c level less than 6.5% at week 104 was 46.3% in both the TCT and SAT groups, whereas the incidence of hypoglycemia, weight gain, or discontinuation of drugs was 16.7% and 62.0% in the TCT and SAT groups, respectively.
- TCT was well-tolerated and had fewer adverse events than SAT.
In conclusion, although each drug's glycemic efficacy in the triple combination therapy was modest, the drug combination led to a 2-year durable glycemic efficacy, with greater than a 2.5% reduction in A1c levels from baseline. Overall, the study results suggest a novel strategy for initial combination therapy in newly diagnosed T2D patients.
In addition, the initial TCT was linked with an improvement in multiple cardiovascular risk factors compared with SAT.
Reference:
Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, Moon MK, Kim DL, Kim TH, Ko E, Lee J, Kim SG. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial. Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15705. Epub ahead of print. PMID: 38853720.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751